Peter A. Pinto, M.D.

Peter A. Pinto, M.D.
Investigator
Urologic Oncology Branch
Head, Prostate Cancer Section

Dr. Pinto is an Investigator and faculty member in the Urologic Oncology Branch of the National Cancer Institute, National Institutes of Health in Bethesda, Md. Following a residency in Urologic Surgery at Long Island Jewish Medical Center - Albert Einstein College of Medicine in New York, he was a Fellow and Clinical Instructor at the Brady Urologic Institute, Johns Hopkins Hospital. Dr. Pinto is a Board Certified Urologic Surgeon specializing in oncology and is the Director of the Urologic Oncology Fellowship Program at the National Cancer Institute. He is nationally and internationally recognized as an expert in the minimally invasive treatment of urologic cancers, specializing in laparoscopic and robotic surgery for prostate, kidney, bladder, and testicular cancer.

Areas of Expertise

1) urologic cancers, 2) laparoscopy, 3) robotic surgery

Contact Info

Peter A. Pinto, M.D.
Center for Cancer Research
National Cancer Institute
Building 10, Hatfield CRC, Room 2W-5940
Bethesda, MD 20892
Ph: 240-858-7200
pintop@mail.nih.gov
Permalink

Dr. Pinto’s scientific mission is development of novel diagnostic and treatment modalities for localized and locally advanced prostate cancer.

Research efforts are centered on investigation of multiparametric MRI (mpMRI) in prostate cancer to improve diagnosis with mpMRI whole-mount pathology correlation and creation of a tumor-directed biopsy device; development of image-guided focal prostate cancer therapy; and evaluation of immunotherapy, molecular targeted therapy or other pharmacotherapies in the management of localized or locally advanced prostate cancer.

 

NIH Scientific Focus Areas:
Biomedical Engineering and Biophysics, Clinical Research
View Dr. Pinto's PubMed Summary.

Selected Recent Publications

  1. Comparison of magnetic resonance imaging and ultrasound (MRI-US) fusion-guided prostate biopsies obtained from axial and sagittal approaches.
    Hong CW, Rais-Bahrami S, Walton-Diaz A, Shakir N, Su D, George AK, Merino MJ, Turkbey B, Choyke PL, Wood BJ, Pinto PA.
    BJU Int. 115: 772-9, 2015. [ Journal Article ]
  2. Diagnostic value of biparametric magnetic resonance imaging (MRI) as an adjunct to prostate-specific antigen (PSA)-based detection of prostate cancer in men without prior biopsies.
    Rais-Bahrami S, Siddiqui MM, Vourganti S, Turkbey B, Rastinehad AR, Stamatakis L, Truong H, Walton-Diaz A, Hoang AN, Nix JW, Merino MJ, Wood BJ, Simon RM, Choyke PL, Pinto PA.
    BJU Int. 115: 381-8, 2015. [ Journal Article ]
  3. Identification by digital immunohistochemistry of intratumoral changes of immune infiltrates after vaccine in the absence of modifications of PBMC immune cell subsets.
    Farsaci B, Jochems C, Grenga I, Donahue RN, Tucker JA, Pinto PA, Merino MJ, Heery CR, Madan RA, Gulley JL, Schlom J.
    Int J Cancer. 135: 862-70, 2014. [ Journal Article ]
  4. Changes observed in multiparametric prostate magnetic resonance imaging characteristics correlate with histopathological development of chronic granulomatous prostatitis after intravesical Bacillus Calmette-Guerin therapy.
    Logan JK, Walton-Diaz A, Rais-Bahrami S, Merino MJ, Turkbey B, Choyke PL, Pinto PA.
    J Comput Assist Tomogr. 38: 274-6, 2014. [ Journal Article ]
  5. Comparison of endorectal coil and nonendorectal coil T2W and diffusion-weighted MRI at 3 Tesla for localizing prostate cancer: correlation with whole-mount histopathology.
    Turkbey B, Merino MJ, Gallardo EC, Shah V, Aras O, Bernardo M, Mena E, Daar D, Rastinehad AR, Linehan WM, Wood BJ, Pinto PA, Choyke PL.
    J Magn Reson Imaging. 39: 1443-8, 2014. [ Journal Article ]

Dr. Pinto is an Investigator and faculty member in the Urologic Oncology Branch of the National Cancer Institute, National Institutes of Health in Bethesda, Md. Following a residency in Urologic Surgery at Long Island Jewish Medical Center - Albert Einstein College of Medicine in New York, he was a Fellow and Clinical Instructor at the Brady Urologic Institute, Johns Hopkins Hospital. Dr. Pinto is a Board Certified Urologic Surgeon specializing in oncology and is the Director of the Urologic Oncology Fellowship Program at the National Cancer Institute. He is nationally and internationally recognized as an expert in the minimally invasive treatment of urologic cancers, specializing in laparoscopic and robotic surgery for prostate, kidney, bladder, and testicular cancer.

Position Keywords Contact Name Contact E-mail Number of Positions
Clinical Fellow - urology, oncology

urology, oncology, fellowship, training

 Peter Pinto

pintop@mail.nih.gov

 Multiple Positions Available
Name Position
Julian Custer Research Biologist (Contr.)
Filipe De Carvalho Clinical Collaborator
Michelle Diffenderfer R.N. Research Nurse
Samuel Gold MRSP Fellow
Tonesia Gross R.N. Research Nurse
Graham Hale MRSP Fellow
Nida Hussain Data Manager (Contr.)
Lisa Mowell Patient Care Coordinator (Contr.)
Luis Nunez Patient Care Coordinator (Contr.)
Charlotte Payne R.N. Research Nurse (Contr.)
Nana Yaqub-Ogun P.A. Physician Assistant
Wild-type human prostate cells from an organoid
Milestones 2017: Seeing Prostate Cancer More Clearly
Peter Pinto, M.D., and Peter Choyke, M.D., use UroNav to improve accuracy of prostate cancer imaging.
Landmarks: Precise Clinical Imaging of Tumors
The JAMA Report: MRI/Ultrasound Fusion Biopsy for Prostate Cancer
The JAMA Report: MRI/Ultrasound Fusion Biopsy for Prostate Cancer